The NIH reports that 70% of medicines given to children have only been studied in adults; therefore, most drugs used to treat diseases in children are used off-label — without an adequate understanding of the appropriate dose, safety, or efficacy. Off-label prescribing has become the treatment of choice because of the lack of clinical trials in the pediatric population.
Explore related content and topics
Blog
Including Children in COVID-19 Trials: Challenges and Opportunities
You may have heard the buzz surrounding a new severe inflammatory condition observed in children that seems to be connected with COVID-19 infection.…
Read Story
Blog
A PRA Expert’s Experience Treating the First Pediatric Patient to Receive CAR T-Cell Therapy
Emily Whitehead was born on May 2nd of 2005, a perfectly healthy baby. When she reached five, her parents noticed bruising on her legs, bleeding…
Read Story
Blog
Children in Clinical Research
Read Story
View all related content and resources for Pediatrics
Explore Insights